Aptorum Group Limited (APM)

NASDAQ: APM · IEX Real-Time Price · USD
1.15
-0.09 (-7.26%)
At close: Sep 30, 2022 4:00 PM
1.17
+0.02 (1.74%)
After-hours: Sep 30, 2022 7:46 PM EDT
-7.26%
Market Cap 41.06M
Revenue (ttm) 1.54M
Net Income (ttm) -25.05M
Shares Out 35.70M
EPS (ttm) -0.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 148,062
Open 1.23
Previous Close 1.24
Day's Range 1.12 - 1.27
52-Week Range 0.86 - 2.72
Beta 0.03
Analysts Buy
Price Target 15.30 (+1,230.4%)
Earnings Date Jul 29, 2022

About APM

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The c... [Read more...]

Industry Biotechnology
IPO Date Dec 18, 2018
Employees 26
Stock Exchange NASDAQ
Ticker Symbol APM
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for APM stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 1,230.43% from the latest price.

Price Target
$15.3
(1,230.43% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022

NEW YORK--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmaceutical company dedicated to meeting u...

1 day ago - Business Wire

Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group”), a clinical-stage biopharmaceutical company focused on the develop...

2 weeks ago - Business Wire

Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to tackling unmet medical needs...

2 weeks ago - Business Wire

7 Hot Small-Cap Stocks to Buy in September

In general, finding small-cap stocks to buy can be somewhat fraught. These are stocks with market capitalizations between roughly $300 million and $2 billion.

Other symbols: TSRIVTVTYTRAZYXI
4 weeks ago - InvestorPlace

Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, auto...

1 month ago - Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

NEW YORK, NY and LONDON, UK, and PARIS, FRANCE / ACCESSWIRE / August 19, 2022 / RedChip Companies will air an interview on Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) a clinical stage biophar...

1 month ago - Accesswire

Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs ...

4 months ago - Business Wire

Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #Neuroblastoma--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical ...

4 months ago - Business Wire

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #Neuroblastoma--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “We”), a clinical stage biopharmaceutical compa...

5 months ago - Business Wire

First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Me...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceuti...

5 months ago - Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company dedicated...

5 months ago - Business Wire

APM Stock Alert: What Is Going on With Little-Known Aptorum Today?

APM stock is skyrocketing on Tuesday following news of an FDA designation. Does this mean the meme stocks crazy isn't over?

8 months ago - InvestorPlace

Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #Neuroblastoma--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical ...

8 months ago - Business Wire

Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but N...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleas...

8 months ago - Business Wire

Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet ...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #autoimmune--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical com...

8 months ago - Business Wire

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceuti...

8 months ago - Business Wire

Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, ...

8 months ago - Business Wire

Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceuti...

9 months ago - Business Wire

Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceuti...

11 months ago - Business Wire

Aptorum Group Limited Interview to Air on Bloomberg U.S.

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM), a clinical stage biopharmaceutical company focused on novel te...

11 months ago - Business Wire

Aptorum To Start Testing SACT-1 In Neuroblastoma Patients

The FDA has signed off Aptorum Group Limited's (NASDAQ: APM) IND application to initiate clinical trials of SACT-1 for neuroblastoma. The IND-opening trial is a bioavailability/food effect study that wi...

1 year ago - Benzinga

Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Mol...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceuti...

1 year ago - Business Wire

Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #biopharmaceutical--Regulatory News: Aptorum Group Limited (NASDAQ: APM, Euronext Paris: APM) (“Aptorum Group” or the “Company”), a clinical stage biopharmac...

1 year ago - Business Wire

Aptorum Shares Move Higher After Interim Data From Staphylococcus Aureus Candidate

Aptorum Group Limited (NASDAQ: APM) announces further interim data from its ongoing Phase 1 trial for ALS-4 targeting Staphylococcus aureus.  Specifically, two additional cohorts (Cohort C & D) of the s...

1 year ago - Benzinga

Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococ...

NEW YORK & LONDON & PARIS--(BUSINESS WIRE)-- #MRSA--Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, ...

1 year ago - Business Wire